Ministry of Health and Long-Term Care

Office of the Deputy Minister

Hepburn Block, 10th Floor
80 Grosvenor Street
Toronto ON M7A 1R3
Tel.: 416 327-4300
Fax: 416 326-1570

Ministère de la Santé et des Soins de longue durée

Bureau du sous-ministre

Édifice Hepburn, 10e étage
80, rue Grosvenor
Toronto ON M7A 1R3
Tél. : 416 327-4300
Téléc. : 416 326-1570

Ontario

OCT 3 1 2016

Mr. Richard Ivey
Chair
MaRS EXCITE Management Board
101 College St.
Toronto ON M5G 1L7

Dear Mr. Ivey:

The Ministry of Health and Long-Term Care (MOHLTC) is committed to working constructively and transparently with the MaRS Excellence in Clinical Innovation Technology Evaluation collaborative (EXCITE) and with industry to ensure EXCITE technologies that receive a positive recommendation for adoption by the EXCITE Management Board (Recommendation) are considered for adoption and diffusion into the Ontario health care system as set out below.

We encourage EXCITE to communicate to its key stakeholders that MOHLTC is committing to work with EXCITE and with industry. In particular, once technologies are prioritized for evaluation through EXCITE, the Office of the Chief Health Innovation Strategist (OCHIS) will assign an Implementation Lead (Lead) from MOHLTC to the technology.

Using resources from EXCITE and MOHLTC, and in partnership with key operational leaders within MOHLTC, the Lead will work with a cross-functional MOHLTC team to identify the key implementation issues associated with the technology should it be considered for adoption at scale in Ontario. These findings will inform the design of the EXCITE study.

While the EXCITE technology study is underway, using these resources, the Lead will work with EXCITE to develop an implementation plan for the technology (Plan), which will include the degree of diffusion across the health system over the relevant time period. The Lead will consult with MOHLTC and health service providers to validate implementation options that include alignment with reimbursement, procurement and other relevant policies.

Should the technology receive a Recommendation at the end of the EXCITE study and achieve the mutually agreed upon milestones in the study, as long as the technology has moved through the EXCITE process in accordance with the original timelines set by EXCITE and subject to any change in funding within the Government of Ontario, MOHLTC will promote the diffusion of the technology into the Ontario health system in the first 18 months to three years as set out in the Plan subject to procurement and other relevant policies.

.../2

As further set out in the Plan, while MOHLTC does not commit to a guaranteed level of gross revenue for the technology, it commits to use its reasonable efforts to work together with the technology originator to achieve gross revenue within the first three years of completion of the EXCITE study up to the amount the technology originator paid to EXCITE to participate in the EXCITE program. Sales made outside of Ontario, and attributable to the EXCITE study, will be included in calculating the level of gross revenue achieved for this purpose.

Sincerely,

Dr. Bob Bell
Deputy Minister